# Estradiol-mediated Inflammation and Central Sensitization in the Pathophysiology of Endometriosis-associated Pelvic Pain

> **NCT07100782** · PHASE3 · RECRUITING · sponsor: **University of Michigan** · enrollment: 130 (estimated)

## Conditions studied

- Endometriosis
- Pelvic Pain

## Interventions

- **DRUG:** Relugolix CT

## Key facts

- **NCT ID:** NCT07100782
- **Lead sponsor:** University of Michigan
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-08
- **Primary completion:** 2028-08
- **Final completion:** 2028-09
- **Target enrollment:** 130 (ESTIMATED)
- **Last updated:** 2026-02-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07100782

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07100782, "Estradiol-mediated Inflammation and Central Sensitization in the Pathophysiology of Endometriosis-associated Pelvic Pain". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07100782. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*